Cost effectiveness of micronised fenofibrate and simvastatin in the short term treatment of type lia and type lib hyperlipidaemia

PharmacoEconomics

Volumn 12, Issue 2 PART II, 1997, Pages 237-246

  Kirchgässler, Klaus U ^a  

^a Laboratoires Fournier SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; CROSSOVER PROCEDURE; DATA BASE; DRUG COST; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LOVASTATIN; MALE; MIDDLE AGED; PROCETOFEN; RETROSPECTIVE STUDIES; SIMVASTATIN;

EID: 0030883899     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199712020-00014     Document Type: Article

References (2)

1. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA 1987; 257: 2176-80
2. Assmann G, Schulte H. Ergebnisse der prospektiven cardiovaskulären Münster (Procam)-Studie. Deutsches Ärzteblatt 1993; 90: B2057-62